Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and ...
The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results